CCM
PCSA icon

Connective Capital Management’s Processa Pharmaceuticals PCSA Stock Holding History

Connective Capital Management’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164K Buy
85,274
+14,538
+21% +$37.6K 0.12% 54
2026
Q1 		$179K Buy
+70,736
New +$193K 0.15% 52

Other funds holding PCSA

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Connective Capital Management's PCSA Position: Q2 2026 in Review

Connective Capital Management increased its Processa Pharmaceuticals (PCSA) stake by 21% in Q2 2026, buying an estimated $37.6K and bringing the position to 85,274 shares worth $164K. The position accounts for 0.12% of the portfolio, ranked #54.

Connective Capital Management first reported a position in PCSA in Q1 2026 and has held it in 2 quarters since. The position peaked at $179K in Q1 2026. 12 funds tracked by Wall St. Rank hold PCSA as of Q2 2026.

  • Connective Capital Management held 85,274 shares of Processa Pharmaceuticals worth $164K as of Q2 2026.
  • Connective Capital Management bought 14,538 Processa Pharmaceuticals shares in Q2 2026, an estimated $37.6K.
  • Processa Pharmaceuticals made up 0.12% of Connective Capital Management's portfolio in Q2 2026, its #54 holding.
  • Connective Capital Management first reported a position in Processa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Connective Capital Management's Processa Pharmaceuticals position peaked at $179K in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2026.

Based on Connective Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.